ucsf logo

Adam L. Boxer, MD, PhD

Neurology • Memory and Cognitive Disorders Neurology
Memory & Aging Mission Bay
415-353-2057
Portrait of Adam L. Boxer
Portrait of Adam L. Boxer
ucsf logo

Adam L. Boxer, MD, PhD

Neurology • Memory and Cognitive Disorders Neurology
Memory & Aging Mission Bay
415-353-2057

On this page

About me

Dr. Adam Boxer is a neurologist at the UCSF Memory and Aging Center who specializes in Alzheimer's disease, frontotemporal dementia and atypical parkinsonism – in particular, corticobasal degeneration and progressive supranuclear palsy.

Boxer obtained his medical and doctoral degrees as part of the Medical Scientist Training Program at New York University School of Medicine, a program funded by the National Institutes of Health. He completed a residency in neurology at Stanford University Medical Center and a fellowship in behavioral neurology at UCSF.

Boxer directs the clinical neurology research unit for the Sandler Neurosciences Center at Mission Bay, as well as the clinical trials program for Alzheimer's disease and frontotemporal dementia at the Memory and Aging Center.

Boxer received the Edwin Boldrey Award from the San Francisco Neurological Society in 2002 for basic research in neurological disease, the 2005 John Douglas French Alzheimer's Foundation Alzheimer's Award and a 2009 Hellman Family Foundation fellowship.

Education & training

Board certification

  • Neurology, American Board of Psychiatry/Neurology-Psychiatry

Fellowship

  • Neurobehavior, UCSF Graduate Medical Education

Degree

  • MD, New York University School of Medicine

Locations

    My research

    Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.

    For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here. The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.